Copyright
©The Author(s) 2017.
World J Gastrointest Oncol. Feb 15, 2017; 9(2): 50-61
Published online Feb 15, 2017. doi: 10.4251/wjgo.v9.i2.50
Published online Feb 15, 2017. doi: 10.4251/wjgo.v9.i2.50
Table 1 Unification of terms relating to anal intraepithelial neoplasia
Normal | LSIL | HSIL | ||
Condyloma or ASCUS | AIN grade I | AIN grade II | AIN grade III | |
Mild dysplasia | Moderate dysplasia | Severe dysplasia |
Table 2 Rates of anal cancer among various populations compiled from various sources
Anal cancer rates among select populations, per 100000 person-years | |
General population | 2[1] |
General population, female | 0.55-2.4[13] |
HIV positive women | 3.9-30[13] |
HIV negative MSM | 5.1[12] |
Solid organ transplant | 10-15[66] |
Prior HPV related malignancy | 0.8-63.8[13] |
HIV positive MSM | 49.5[12] |
Colon cancer in general population | 41[2] |
Table 3 Progression rates of anal intraepithelial neoplasia to squamous cell carcinoma
Progression | No. patients | Rate of progression | Median or average progression time | Ref. |
AIN II/III to SCC | 72 | 11% | 42 mo | [33] |
AIN III to SCC | 35 | 8.6% | 53 mo | [34] |
AIN I to AIN III | 199 | 12.6% (8.1/100 person-years) | 18 mo | [35] |
ASCUS/AIN I to AIN II/III | 556 | 24.5% (10.5/100 person-years) | 36 mo | [36] |
HSIL to SCC | 138 | 19.6% | 57 mo. w/prevalent HSIL; 64 mo. w/incident HSIL | [37] |
- Citation: Roberts JR, Siekas LL, Kaz AM. Anal intraepithelial neoplasia: A review of diagnosis and management. World J Gastrointest Oncol 2017; 9(2): 50-61
- URL: https://www.wjgnet.com/1948-5204/full/v9/i2/50.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v9.i2.50